NASDAQ: SRRK

Scholar Rock Holding Corporation

Healthcare | Biotechnology

No licensed closing price on file for SRRK. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Scholar Rock Holding Corporation (NASDAQ: SRRK) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 00:35 UTC.

What Scholar Rock Holding Corporation does

Scholar Rock is a global biopharmaceutical company focused on developing treatments for spinal muscular atrophy and other rare neuromuscular diseases. The company's core technology targets the transforming growth factor beta superfamily, enabling the creation of monoclonal antibodies that selectively inhibit latent forms of growth factors, particularly myostatin. Its lead candidate, apitegromab, is a fully human monoclonal antibody that inhibits myostatin activation to increase muscle mass and strength, with positive Phase 3 data reported for SMA treatment.

Summarized from Scholar Rock Holding Corporation’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-06-05
Return on equity	-51.68%
Debt/equity	0.77

Revenue, margins & earnings

Net income
Taxes & interest
Operating costs
Net loss year

Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-09-25

2026-09-25Chief Operating OfficerGift-48,034—
2026-09-23Chief Executive OfficerGift-36,652—
2026-07-06DirectorSale-1,470$79.7K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

FMR LLC17,995,241$989.74M+5.5%
Siren, L.L.C.9,575,013$526.63M-11.6%
BlackRock, Inc.9,494,084$522.17M+152.3%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-06-03AuditorChanges in registrant's certifying accountantDeloitte & Touche LLPEstimatedSEC 8-K →
2025-05-12AuditorChanges in registrant's certifying accountantErnst & Young LLPEstimatedSEC 8-K →
2025-04-28Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersDavid HallalAuthoritativeSEC 8-K →

Company news

View all →

Questions this page answers

What does Scholar Rock Holding Corporation do?

Scholar Rock is a global biopharmaceutical company focused on developing treatments for spinal muscular atrophy and other rare neuromuscular diseases.

When did SRRK last file with the SEC?

Scholar Rock Holding Corporation's most recent SEC filing on record is a 8-K filed 2026-06-05. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 00:35 UTC. This page is also available as JSON at /api/data?ticker=SRRK and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for SRRK and 5,000+ tickers.

Create a free account — keep SRRK

For your agent

GET /api/data?ticker=SRRK

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt